The Promising Potential of Combining Pelareorep with mFOLFIRINOX In the ever-evolving landscape of cancer treatment, groundbreaking research often heralds new hope. A striking example is the recent findings from the safety run-in portion of the GOBLET study, presented at the 2025 Gastrointestinal Cancers Symposium. This study explores the combination of pelareorep with mFOLFIRINOX, with or … Read more
Revolutionizing Pancreatic Cancer Treatment with Surufatinib and TAS-102 The phase 2 trial results present a hopeful future for pancreatic cancer treatment, especially for patients with refractory metastatic pancreatic ductal adenocarcinoma (mPDAC). Adding surufatinib, commercially known as Sulanda, to TAS-102 has shown promising survival outcomes and manageable toxicity in late-line therapy. This innovative combination, discussed at … Read more
Personalized Treatment in Breast Cancer: Paving the Way for the Future The recent FDA breakthrough therapy designation for the DCISionRT test represents a significant leap in personalized medicine for breast cancer care. As a tool designed to evaluate individual risks and benefits of radiation therapy for ductal carcinoma in situ (DCIS), it embodies the extremely … Read more
Unlocking the Future of Cancer Treatment with Vaccine Advances Recent breakthroughs in cancer vaccine research herald an exciting era in oncology. UK researchers have published a pioneering thought leadership report in Cambridge Prisms: Precision Medicine, highlighting the transformative potential of cancer vaccines. As neoantigen-based vaccines emerge, the prospect of personalized cancer treatment becomes a tangible … Read more
The Future of Immune Oncology Drug Development The recent advancement of R-5780 through FDA clearance marks a pivotal moment in immune oncology drug development. As researchers push the boundaries of synthetic biology, this novel therapeutic approach not only showcases the potential for heightened immune responses but also establishes a foundation for future innovations in cancer … Read more
Breakthrough in Cancer Treatment: FDA’s Breakthrough Therapy Designation The U.S. Food and Drug Administration (FDA) has granted a breakthrough therapy designation (BTD) to letetresgene autoleucel (lete-cel) for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS). This designation marks a significant advancement in cancer therapy, offering new hope for patients who have … Read more
Revolutionizing Renal Cancer Treatment: The Impact of Pembrolizumab The landscape of treating clear cell renal cell carcinoma (ccRCC) has been significantly upgraded with the introduction of pembrolizumab. Recent findings from the KEYNOTE-564 trial highlight the drug’s success in adjuvant treatment, demonstrating a notable improvement in overall survival (OS) and disease-free survival (DFS) for patients at … Read more